Renalytix - ROE 2020-2024 | RNLXY
Current and historical return on equity (ROE) values for Renalytix - (RNLXY) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Renalytix - ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2024-09-30 | $-0.03B | $-0.01B | 294.74% |
| 2024-06-30 | $-0.03B | $-0.01B | 471.43% |
| 2024-03-31 | $-0.04B | $-0.01B | 1138.46% |
| 2023-12-31 | $-0.04B | $-0.01B | -1025.00% |
| 2023-09-30 | $-0.04B | $0.00B | -521.21% |
| 2023-06-30 | $-0.05B | $0.01B | -339.62% |
| 2023-03-31 | $-0.04B | $0.02B | -202.60% |
| 2022-12-31 | $-0.04B | $0.01B | -190.91% |
| 2022-09-30 | $-0.05B | $0.02B | -150.40% |
| 2022-06-30 | $-0.05B | $0.03B | -108.43% |
| 2022-03-31 | $-0.05B | $0.03B | -97.09% |
| 2021-12-31 | $-0.04B | $0.05B | -68.48% |
| 2021-09-30 | $-0.04B | $0.06B | -51.01% |
| 2021-06-30 | $-0.04B | $0.07B | -43.08% |
| 2021-03-31 | $-0.03B | $0.08B | -41.48% |
| 2020-12-31 | $-0.02B | $0.09B | -42.11% |
| 2020-09-30 | $-0.02B | $0.09B | -62.14% |
| 2020-06-30 | $-0.01B | $0.02B | -250.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.043B | $0.003B |
| Renalytix plc is an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. Renalytix plc, formerly known as RENALYTIX AI, is based in NEW YORK. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $48.084B | 58.67 |
| Tempus AI (TEM) | United States | $12.183B | 0.00 |
| Doximity (DOCS) | United States | $9.342B | 38.47 |
| Hims & Hers Health (HIMS) | United States | $8.418B | 68.48 |
| IRhythm Technologies (IRTC) | United States | $5.504B | 0.00 |
| Hinge Health (HNGE) | United States | $3.224B | 0.00 |
| Privia Health (PRVA) | United States | $2.884B | 180.38 |
| Inspire Medical Systems (INSP) | United States | $2.509B | 41.51 |
| Heartflow (HTFL) | United States | $2.383B | 0.00 |
| 10x Genomics (TXG) | United States | $2.011B | 0.00 |
| Enovis (ENOV) | United States | $1.715B | 9.01 |
| Omnicell (OMCL) | United States | $1.576B | 32.22 |
| Azenta (AZTA) | United States | $1.364B | 59.50 |
| Phreesia (PHR) | United States | $1.304B | 0.00 |
| Schrodinger (SDGR) | United States | $1.299B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.276B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.900B | 0.00 |
| Claritev (CTEV) | United States | $0.715B | 0.00 |
| Talkspace (TALK) | United States | $0.538B | 108.33 |
| Butterfly Network (BFLY) | United States | $0.536B | 0.00 |
| Veradigm (MDRX) | United States | $0.523B | 0.00 |
| Standard BioTools (LAB) | United States | $0.477B | 0.00 |
| Evolent Health (EVH) | United States | $0.466B | 0.00 |
| Carlsmed (CARL) | United States | $0.349B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.348B | 0.00 |
| TruBridge (TBRG) | United States | $0.306B | 14.05 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.291B | 0.00 |
| CapsoVision (CV) | United States | $0.239B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.212B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.200B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.172B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.170B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.160B | 0.00 |
| CareCloud (CCLD) | United States | $0.133B | 7.28 |
| EUDA Health Holdings (EUDA) | Singapore | $0.110B | 0.00 |
| Outset Medical (OM) | United States | $0.085B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.067B | 0.00 |
| American Well (AMWL) | United States | $0.066B | 0.00 |
| Pulmonx (LUNG) | United States | $0.061B | 0.00 |
| HeartBeam (BEAT) | United States | $0.054B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.049B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.045B | 0.00 |
| 111 (YI) | China | $0.035B | 0.00 |
| Precipio (PRPO) | United States | $0.031B | 0.00 |
| Predictive Oncology (POAI) | United States | $0.027B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.025B | 0.00 |
| Zhongchao (ZCMD) | China | $0.017B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.015B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.010B | 0.00 |
| Movano (MOVE) | United States | $0.009B | 0.00 |
| HeartSciences (HSCS) | United States | $0.008B | 0.00 |
| PROFUSA (PFSA) | United States | $0.008B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.007B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.002B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.001B | 0.00 |